- Home
- SRTS vs MDXH Comparison
SRTS vs MDXH Comparison
Compare SRTS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- MDXH
- Stock Information
- Founded
- SRTS 2010
- MDXH 2003
- Country
- SRTS United States
- MDXH Belgium
- Employees
- SRTS N/A
- MDXH N/A
- Industry
- SRTS Medical/Dental Instruments
- MDXH
- Sector
- SRTS Health Care
- MDXH
- Exchange
- SRTS Nasdaq
- MDXH Nasdaq
- Market Cap
- SRTS 106.0M
- MDXH 100.5M
- IPO Year
- SRTS 2016
- MDXH 2021
- Fundamental
- Price
- SRTS $8.89
- MDXH $1.88
- Analyst Decision
- SRTS Strong Buy
- MDXH Strong Buy
- Analyst Count
- SRTS 2
- MDXH 2
- Target Price
- SRTS $12.50
- MDXH $7.00
- AVG Volume (30 Days)
- SRTS 262.3K
- MDXH 163.0K
- Earning Date
- SRTS 11-14-2024
- MDXH 11-06-2024
- Dividend Yield
- SRTS N/A
- MDXH N/A
- EPS Growth
- SRTS N/A
- MDXH N/A
- EPS
- SRTS 0.57
- MDXH N/A
- Revenue
- SRTS $41,308,000.00
- MDXH $84,708,000.00
- Revenue This Year
- SRTS $55.14
- MDXH $26.39
- Revenue Next Year
- SRTS $21.75
- MDXH $18.68
- P/E Ratio
- SRTS $15.62
- MDXH N/A
- Revenue Growth
- SRTS 65.62
- MDXH 33.01
- 52 Week Low
- SRTS $2.05
- MDXH $0.35
- 52 Week High
- SRTS $9.20
- MDXH $4.64
- Technical
- Relative Strength Index (RSI)
- SRTS 75.94
- MDXH 47.88
- Support Level
- SRTS $6.70
- MDXH $1.55
- Resistance Level
- SRTS $9.20
- MDXH $1.82
- Average True Range (ATR)
- SRTS 0.56
- MDXH 0.15
- MACD
- SRTS 0.21
- MDXH -0.01
- Stochastic Oscillator
- SRTS 89.08
- MDXH 47.83
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.